PTJ
CSTL icon

Paul Tudor Jones’s Castle Biosciences CSTL Stock Holding History

Paul Tudor Jones’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$345K Sell
14,462
-208,520
-94% -$4.64M ﹤0.01% 3043
2026
Q1 		$5.47M Buy
222,982
+55,804
+33% +$1.83M 0.01% 1115
2025
Q4 		$6.5M Buy
167,178
+81,743
+96% +$2.64M 0.01% 997
2025
Q3 		$1.95M Buy
85,435
+8,981
+12% +$182K ﹤0.01% 1825
2025
Q2 		$1.56M Sell
76,454
-94,928
-55% -$1.76M ﹤0.01% 1836
2025
Q1 		$3.43M Buy
171,382
+101,306
+145% +$2.51M 0.01% 998
2024
Q4 		$1.87M Buy
70,076
+20,586
+42% +$627K 0.01% 1310
2024
Q3 		$1.41M Buy
49,490
+15,552
+46% +$396K 0.01% 1418
2024
Q2 		$739K Buy
33,938
+20,941
+161% +$467K ﹤0.01% 1618
2024
Q1 		$288K Buy
+12,997
New +$283K ﹤0.01% 1877
2023
Q1 		– Sell
-58,903
Closed -$1.39M – 2502
2022
Q4 		$1.39M Buy
58,903
+44,665
+314% +$1.04M 0.03% 864
2022
Q3 		$371K Buy
+14,238
New +$399K 0.01% 1618
2021
Q2 		– Sell
-3,101
Closed -$212K – 1650
2021
Q1 		$212K Buy
+3,101
New +$233K ﹤0.01% 1411

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paul Tudor Jones's CSTL Position: Q2 2026 in Review

Paul Tudor Jones reduced its Castle Biosciences (CSTL) stake by 94% in Q2 2026, selling an estimated $4.64M and leaving 14,462 shares worth $345K. The position accounts for ﹤0.01% of the portfolio, ranked #3043.

Paul Tudor Jones first reported a position in CSTL in Q1 2021 and has held it in 13 quarters since. The position peaked at $6.5M in Q4 2025. 175 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Paul Tudor Jones held 14,462 shares of Castle Biosciences worth $345K as of Q2 2026.
  • Paul Tudor Jones sold 208,520 Castle Biosciences shares in Q2 2026, an estimated $4.64M.
  • Castle Biosciences made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #3043 holding.
  • Paul Tudor Jones first reported a position in Castle Biosciences in Q1 2021 and has held it in 13 quarters since.
  • Paul Tudor Jones's Castle Biosciences position peaked at $6.5M in Q4 2025.
  • 175 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.